On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, who discussed the trial results with The ASCO Post at the 2021 San Antonio Breast Cancer Symposium.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.